Emerging Targets and Cellular Therapy for Relapsed Refractory Multiple Myeloma: A Systematic Review

Kazandjian, 2016, Multiple myeloma epidemiology and survival: a unique malignancy, Semin Oncol, 43, 676, 10.1053/j.seminoncol.2016.11.004 Abdallah, 2020, Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response, Blood Cancer J, 10, 1 Majithia, 2016, Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents, Leukemia, 30, 2208, 10.1038/leu.2016.147 Kumar, 2012, Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study, Leukemia, 26, 149, 10.1038/leu.2011.196 Dimopoulos, 2016, Daratumumab, lenalidomide, and dexamethasone for multiple myeloma, N Eng J Med, 375, 1319, 10.1056/NEJMoa1607751 Dimopoulos, 2018, Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX, Haematologica, 103, 2088, 10.3324/haematol.2018.194282 Spencer, 2018, Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR, Haematologica, 103, 2079, 10.3324/haematol.2018.194118 Dimopoulos, 2020, Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study, Lancet, 396, 186, 10.1016/S0140-6736(20)30734-0 Giralt, 2015, Biol Blood Marrow Transplant, 21, 2039, 10.1016/j.bbmt.2015.09.016 Ramos, 2011, Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy, Expert Opin Biol Ther, 11, 855, 10.1517/14712598.2011.573476 Guest, 2005, The role of extracellular spacer regions in the optimal design of chimeric immune receptors: evaluation of four different scFvs and antigens, J Immunother, 28, 203, 10.1097/01.cji.0000161397.96582.59 Jensen, 2010, Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans, Biol Blood Marrow Transplant, 16, 1245, 10.1016/j.bbmt.2010.03.014 Till, 2008, Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells, Blood, 112, 2261, 10.1182/blood-2007-12-128843 Kaliński, 1999, T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal, Immunol Today, 20, 561, 10.1016/S0167-5699(99)01547-9 Drake, 2006, Mechanisms of immune evasion by tumors, Adv Immunol, 90, 51, 10.1016/S0065-2776(06)90002-9 Smith, 2016, Chimeric antigen receptor (CAR) T cell therapy for malignant cancers: summary and perspective, J Cell Immunother, 2, 59, 10.1016/j.jocit.2016.08.001 Holstein, 2020, CAR T-cell therapy in hematologic malignancies: a voyage in progress, Clin Pharmacol Ther, 107, 112, 10.1002/cpt.1674 Tokarew, 2018, Teaching an old dog new tricks: next-generation CAR T cells, Br J Cancer, 120, 26, 10.1038/s41416-018-0325-1 Chmielewski, 2015, TRUCKs: the fourth generation of CARs, Expert Opin Biol Ther, 15, 1145, 10.1517/14712598.2015.1046430 Varmus, 1998, Retroviruses, Science, 240, 1427, 10.1126/science.3287617 Mann, 1983, Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirus, Cell, 153, 10.1016/0092-8674(83)90344-6 Naldini, 1996, In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector, Science, 272, 263, 10.1126/science.272.5259.263 Muranski, 2006, Increased intensity lymphodepletion and adoptive immunotherapy–how far can we go?, Nat Clin Pract Oncol, 3, 668, 10.1038/ncponc0666 Gattinoni, 2005, Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells, J Exp Med, 202, 907, 10.1084/jem.20050732 Ninomiya, 2015, Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs, Blood, 125, 3905, 10.1182/blood-2015-01-621474 Turtle, 2016, Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells, Sci Transl Med, 8, 10.1126/scitranslmed.aaf8621 Davila, 2014, Efficacy and toxicity management of 19–28z CAR T cell therapy in B cell acute lymphoblastic leukemia, Sci TranslMed, 6 Kochenderfer, 2012, B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells, Blood, 119, 2709, 10.1182/blood-2011-10-384388 Hirayama, 2019, Toxicities of CD19 CAR-T cell immunotherapy, Am J Hematol, 94, S42, 10.1002/ajh.25445 Neelapu, 2019, Managing the toxicities of CAR T-cell therapy, Hematol Oncol, 37, 48, 10.1002/hon.2595 Sheth, 2020, Taming the beast: CRS and ICANS after CAR T-cell therapy for ALL, Bone Marrow Transplant Mackay, 2004, The role of the BAFF/APRIL system in B cell homeostasis and lymphoid cancers, Curr Opin Pharmacol, 4, 347, 10.1016/j.coph.2004.02.009 Tai, 2016, APRIL and BCMA promote human multiple myeloma growth andimmunosuppression in the bone marrow microenvironment, Blood, 127, 3225, 10.1182/blood-2016-01-691162 Raje, 2019, Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma, N Engl J Med, 380, 1726, 10.1056/NEJMoa1817226 Zhao, 2018, A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma, J Hematol Oncol, 11, 141, 10.1186/s13045-018-0681-6 Munshi, 2021, Idecabtagene vicleucel in relapsed and refractory multiple myeloma, N Eng J Med, 384, 705, 10.1056/NEJMoa2024850 Madduri, 2020, CARTITUDE-1: phase 1b/2 study of ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T cell therapy, in relapsed/refractory multiple myeloma, Blood, 136, 22, 10.1182/blood-2020-136307 Mailankody, 2020, An allogeneic first-in-human study of the anti-BCMA ALLO-715 and the anti-CD52 ALLO-647 in relapsed/refractory multiple myeloma Garfall, 2018, Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma, JCI Insight, 3, 1, 10.1172/jci.insight.120505 Garfall, 2015, Chimeric antigen receptor T cells against CD19 for multiple myeloma, N Eng J Med, 373, 1040, 10.1056/NEJMoa1504542 Yan, 2019, A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial, Lancet Haematol, 6, e521, 10.1016/S2352-3026(19)30115-2 Jiang, 2020, Clinical results of a multicenter study of the first-in-human dual BCMA and CD19 targeted novel platform fast CAR-T cell therapy for patients with relapsed/refractory multiple myeloma Cowan, 2019, Efficacy and safety of fully human BCMA CAR T cells in combination with a gamma secretase inhibitor to increase BCMA surface expression in patients with relapsed or refractory multiple myeloma, Blood, 134, 204, 10.1182/blood-2019-129405 Guo, 2016, CD138-directed adoptive immunotherapy of chimeric antigen receptor (CAR)-modified T cells for multiple myeloma, J Cell Immunother, 2, 28, 10.1016/j.jocit.2014.11.001 Sallman, 2019, Results from the completed dose-escalation of the hematological arm of the phase I think study evaluating multiple infusions of NKG2D-based CAR T-cells as standalone therapy in relapse/refractory acute myeloid leukemia and myelodysplastic syndrome patients, Blood, 134, 3826, 10.1182/blood-2019-128020 Mihara, 2012, T-cell immunotherapy with a chimeric receptor against CD38 is effective in eliminating myeloma cells, Leukemia, 26, 365, 10.1038/leu.2011.205 Berdeja, 2019, Updated results from an ongoing phase 1 clinical study of bb21217 anti-BCMA CAR T cell therapy, Blood, 134, 927, 10.1182/blood-2019-126660 Liebisch, 2005, CD44v6, a target for novel antibody treatment approaches, is frequently expressed in multiple myeloma and associated with deletion of chromosome arm 13q, Haematologica, 90, 489 Casucci, 2013, CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma, Blood, 122, 3461, 10.1182/blood-2013-04-493361 Ramani, 2014, Chemotherapy stimulates syndecan-1 shedding: a potentially negative effect of treatment that may promote tumor relapse, Matrix Biol, 35, 215, 10.1016/j.matbio.2013.10.005 Malaer, 2017, CS1 (SLAMF7, CD319) is an effective immunotherapeutic target for multiple myeloma, Am J Cancer Res, 7, 1637 Chu, 2014, Genetic modification of T cells redirected toward CS1 enhances eradication of myeloma cells, Clin Cancer Res, 20, 3989, 10.1158/1078-0432.CCR-13-2510 Gogishvili, 2017, SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF71normal lymphocytes, Blood, 130, 2838, 10.1182/blood-2017-04-778423 Smith, 2019, GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells, Sci Transl Med, 11, 1, 10.1126/scitranslmed.aau7746 Spear, 2013, NKG2D ligands as therapeutic targets, Cancer Immun., 13, 8 Sotillo, 2015, Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19immunotherapy, Cancer Discov., 5, 1282, 10.1158/2159-8290.CD-15-1020 de Larrea, 2020, Defining an optimal dual-targeted CAR T-cell therapy approach simultaneously targeting BCMA and GPRC5D to prevent BCMA escape-driven relapse in multiple myeloma, Blood Cancer Discov, 1, 146, 10.1158/2643-3230.BCD-20-0020 Kloss, 2013, Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells, Nat Biotechnol, 31, 71, 10.1038/nbt.2459 Sanchez, 2012, Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival, Br J Haematol, 158, 727, 10.1111/j.1365-2141.2012.09241.x Brudno, 2018, T cells genetically modified to express an anti-B-Cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma, J Clin Oncol, 36, 2267, 10.1200/JCO.2018.77.8084 Costello, 2020, Phase 1/2 study of the safety and response of P-BCMA-101 CAR-T cells in patients with relapsed/refractory (r/r) multiple myeloma (MM) (PRIME) with novel therapeutic strategies Zhao, 2016, PiggyBac transposon vectors: the tools of the human gene encoding, Transl Lung Cancer Res, 5, 120 Lin, 2017, CD8+ anti-BCMA CAR T-cells effectively kill human multiple myeloma cells in vitro and in vivo, Blood, 130, 3067 Yu, 2019, Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity, Mol Cancer, 18, 125, 10.1186/s12943-019-1057-4 Di Stasi, 2011, Inducible apoptosis as a safety switch for adoptive cell therapy, N Engl J Med, 65, 1673, 10.1056/NEJMoa1106152 Bonini, 1997, HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia, Science, 276, 1719, 10.1126/science.276.5319.1719 Sato, 2007, Engineered human TMPK/AZT as a novel enzyme/prodrug axis for suicide gene therapy, Mol Ther, 15, 962, 10.1038/mt.sj.6300122 Griffioen, 2009, Retroviral transfer of human CD20 as a suicide gene for adoptive T-cell therapy, Haematologica, 94, 1316, 10.3324/haematol.2008.001677 Fedorov, 2013, PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses, Sci Transl Med, 5, 10.1126/scitranslmed.3006597 Srivastava, 2019, Logic-gated ROR1 chimeric antigen receptor expression rescues T cell-mediated toxicity to normal tissues and enables selective tumor targeting, Cancer Cell, 35, 489, 10.1016/j.ccell.2019.02.003 Kim, 2015, Redirection of genetically engineered CAR-T cells using bifunctional small molecules, J Am Chem Soc, 137, 2832, 10.1021/jacs.5b00106 Tamada, 2012, Redirecting gene-modified T cells toward various cancer types using tagged antibodies, Clin Cancer Res, 18, 6436, 10.1158/1078-0432.CCR-12-1449 Wu, 2015, Remote control of therapeutic T cells through a small molecule-gated chimeric receptor, Science, 350, aab4077, 10.1126/science.aab4077 Yan, 2021, Sequential CD19 and BCMA-specific CAR T-cell treatment elicits sustained remission of relapsed and/or refractory myeloma, Cancer Med, 10, 563, 10.1002/cam4.3624 Lin, 2020, Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy in patients with relapsed and refractory multiple myeloma: updated results from phase 1 CRB-401 study Hao, 2020, Two-year follow-up of investigator initiated phase 1 trials of the safety and efficacy of fully human anti-BCMA CAR T Cells (CT053) in relapsed/refractory multiple myeloma Chen, 2020, Results from lummicar-1: a phase 1 study of fully human B-cell maturation antigen-specific CAR T cells (Ct053) in Chinese subjects with relapsed and/or refractory multiple myeloma Kumar, 2020, Results from lummicar-2: a phase 1b/2 study of fully human B-cell maturation antigen-specific CAR T cells (CT053) in patients with relapsed and/or refractory multiple myeloma An, 2020, An anti-BCMA CAR T-cell therapy (C-CAR088) shows promising safety and efficacy profile in relapsed or refractory multiple myeloma Mailankody, 2020, Orvacabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed/refractory multiple myeloma (RRMM): update of the phase 1/2 EVOLVE study (NCT03430011), J Clin Oncol, 38, S8504, 10.1200/JCO.2020.38.15_suppl.8504 Hao, 2020, Two-year follow-up of investigator-initiated phase 1 trials of the safety and efficacy of fully human anti-BCMA CAR T Cells (CT053) in relapsed/refractory multiple myeloma, Blood, 136, 27, 10.1182/blood-2020-140156 Han, 2019, The phase I clinical study of CART targeting BCMA with humanized alpaca-derived single domain antibody as antigen recognition domain, J Clin Oncol, 37, 2535, 10.1200/JCO.2019.37.15_suppl.2535 Cohen, 2019, B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma, J Clin Invest, 129, 2210, 10.1172/JCI126397 Baumeister, 2019, Phase I trial of autologous CAR T cells targeting NKG2D ligands in patients with AML/MDS and multiple myeloma, Cancer Immunol Res, 7, 100, 10.1158/2326-6066.CIR-18-0307 Xu, 2019, Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma, PNAS, 116, 9543, 10.1073/pnas.1819745116 Liu, 2018, Remission observed from a phase I clinical study of CAR-T therapy with safety switch targeting BCMA for patients with relapsed/refractory multiple myeloma, J Clin Oncol, 36, 8020, 10.1200/JCO.2018.36.15_suppl.8020